MGMeredith GreeneMDVideoHIVInternational Workshop on Aging & HIV 2017Current reality: The San Francisco experience | Meredith Greene, MDView Video
MTMadhav ThambisettyMDVideoHIVInternational Workshop on Aging & HIV 2017OMICS in the context of aging and Alzheimer's disease | Madhav Thambisetty, MDView Video
VideoHIVInternational Workshop on Aging & HIV 2017The biology of superagers | Nir Barzilai, MDView Video
VideoHIVInternational Workshop on Aging & HIV 2017Clinical Trials Targeting Aging to Extend Healthy Lifespan | Jamie Justice, PhDView Video
SlidesetOncologyInternational Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2017PK and PKPD considerations for dose selection in the development of pembrolizumab | Dinesh de Alwis, PhDView Slideset
SlidesetOncologyInternational Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2017Modeling of cardiac biomarkers in breast cancer patients treated with anthracycline and trastuzumab regimensView Slideset
SlidesetOncologyInternational Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2017Clinical case discussions | Nielka van Erp, PharmD, PhDView Slideset
SlidesetOncologyInternational Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2017Trough dabrafenib plasma concentrations can predict occurrence of adverse effects requiring dose reduction in metastatic melanomaView Slideset
MRMark RatainMDSlidesetOncologyInternational Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2017Opening Lecture: Inter- and intravariability in PK | Mark Ratain, MDView Slideset
SlidesetOncologyInternational Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2017Physiologically based PK model vs. Population PK approach during drug development | Italo Poggesi, PhDView Slideset
SlidesetOncologyInternational Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2017Model-based TDM for oncology drugs | Ron Keizer, PharmD, PhDView Slideset
